Next, to examine the severity of liver disease using the semiquantitative scoring developed by Kleiner et al28, we performed ordinal regression analyses and found that Psd3 ASO treatment reduced the severity of steatosis and lobular inflammation scores, and the NAFLD activity score (NAS), although the liver fibrosis score did not change significantly (Fig. 6g–j). Here, PSD3 is linked to metabolic dysfunction-associated steatotic liver disease.